Nextcure

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO & BELTSVILLE, Mass.--(BUSINESS WIRE)---- $NXTC #ClassAction--Shareholder rights law firm Robbins LLP announces that an investor of NextCure, Inc. (NASDAQ: NXTC) filed a class action against the Company for: (i) alleged violations of the Securities Exchange Act of 1934 between November 5, 2019 and July 14, 2020; and (ii) pursuant to the Securities Act of 1933 for misstatements in connection with its November 2019 secondary public offering ("SPO"). NextCure is a clinical-stage biopharmaceutical company that d

Shareholder Alert: Robbins LLP Announces That An Investor of NextCure, Inc. (NXTC ) Filed a Class Action Complaint Against the Company

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)-- #CLASSACTION--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of NextCure Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) resulting from allegations that NextCure might have issued misleading information to the investing public. If you purchased NextCure securities, and/or would like to discuss your legal rights and options please visit NXTC Shareholder Investigation or contact Matth

NXTC LOSSES ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

NXTC INVESTOR ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC) between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for NextCure investors under the federal securities laws. To join the NextCure class action, go to http://www.rosenlegal.com/cases-register-1952.html or call Phillip Kim, Esq. toll-free

NXTC EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against NextCure, Inc. – NXTC

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #classaction--The Law Offices of Frank R. Cruz announces an investigation of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On January 13, 2020, NextCure disclosed that Eli Lilly and Company had ended its collaboration agreement for the research and development of the Company’s leading product candid

The Law Offices of Frank R. Cruz Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)----Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against NextCure, Inc. (“NextCure” or the “Company”), certain directors and officers of the Company, and the underwriters of NextCure’s November 2019 public offering (collectively, “Defendants”).

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against NextCure Inc.

BELTSVILLE, Md., Sept.  14, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D., to its board of directors as of September 10, 2020. Dr. Houston has more than 30 years of experience in the pharmaceutical and biotech industry and currently serves as president and chief executive officer of Arvinas, Inc. In addition, Judith Li has announced that she is stepping down from the company’s board of directors.

NextCure Announces Appointment of John G. Houston, Ph.D.

BELTSVILLE, Md., Sept.  08, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15th at 4:15 pm Eastern time.

NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference

BELTSVILLE, Md., Aug.  06, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2020 financial results and provided a business update.

NextCure Reports Second Quarter 2020 Financial Results

BELTSVILLE, Md., Aug.  05, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BTIG Virtual Biotechnology Conference on August 11th at 9:30 am Eastern time.

NextCure to Present at BTIG Virtual Biotechnology Conference

NextCure, Inc. (NXTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will NextCure, Inc. (NXTC) Report Negative Q2 Earnings?

BELTSVILLE, Md., July  13, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an interim update for the Phase 2 portion of its NC318 monotherapy phase 1/2 trial.

NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer

BELTSVILLE, Md., July  07, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC410, a novel immunomedicine developed to block immune suppression mediated by an immune modulator called LAIR-1.

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

BELTSVILLE, Md., May  29, 2020  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology (ASCO20) Annual Meeting. NC318 is a monoclonal antibody targeting Siglec-15 (S15), a novel immunomodulatory protein that is expressed on highly immunosuppressive cells called M2 macrophages and on tumor cells.

NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

Golar LNG

Gossamer Bio Inc

GW Pharmaceuticals

Lexinfintech Hlds

SINA

Millicom International Cellular S.A.

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino.

7 High-Risk Stocks For Market Gamblers

NextCure Inc (NXTC) delivered earnings and revenue surprises of 156.90% and 1621.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates

The company cited patient safety concerns and the current strains on hospitals as the reasons for the postponements.

NextCure Delays 2 Clinical Trials Due to Coronavirus

BELTSVILLE, Md., April  13, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the company's clinical trial activities due to the impact of the COVID-19 pandemic.

NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic

BELTSVILLE, Md., March  30, 2020  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of product development and commercialization experience and previously held leadership positions at Pfizer Oncology and Eli Lilly and Company. In addition, Timothy M. Shannon, M.D. notified NextCure that he is stepping down from the company’s board of directors.

NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors

NextCure (NXTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

News for Nextcure Stock (NXTC)